Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Type 2 Diabetes Mellitus with Coronary Heart Disease at High Cardiovascular Risk
2004-004226-28Phase 3Terminated
- Sponsor
- Takeda
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pioglitazone in type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis, sponsored by Takeda. Primary endpoint: Change of MMP-9 on day 28 vs. day 0. Started May 2005; status: terminated.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on 2004-004226-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004226-28.